Ranbaxy Laboratories Ltd (RANB.NS)

RANB.NS on National Stock Exchange of India

633.35INR
6:20am EDT
Price Change (% chg)

Rs10.05 (+1.61%)
Prev Close
Rs623.30
Open
Rs625.90
Day's High
Rs635.30
Day's Low
Rs622.50
Volume
813,121
Avg. Vol
1,129,946
52-wk High
Rs667.60
52-wk Low
Rs305.20

RANB.NS

Chart for RANB.NS

About

Ranbaxy Laboratories Limited is an integrated international pharmaceuticals company. The Company is engaged in the marketing, production and distribution of pharmaceutical products. The Company’s business activity falls within a single primary business segment viz. Pharmaceutical. The Company has ground operations in over 40... (more)

Overall

Beta: 0.65
Market Cap (Mil.): Rs264,636.31
Shares Outstanding (Mil.): 424.57
Dividend: --
Yield (%): --

Financials

  RANB.NS Industry Sector
P/E (TTM): -- 32.70 33.67
EPS (TTM): -20.63 -- --
ROI: -- 18.12 17.39
ROE: -- 18.79 18.21
Search Stocks

Indian drugmaker Ranbaxy still has exclusive rights for Nexium generic: CEO

MUMBAI - Indian drugmaker Ranbaxy Laboratories still has exclusive rights to the launch of AstraZeneca's heartburn drug Nexium in the United States, it said on Tuesday, despite regulatory concern over the manufacturing process.

28 Oct 2014

Indian drugmaker Ranbaxy still has exclusive rights for Nexium generic -CEO

MUMBAI, Oct 28 - Indian drugmaker Ranbaxy Laboratories still has exclusive rights to the launch of AstraZeneca's heartburn drug Nexium in the United States, it said on Tuesday, despite regulatory concern over the manufacturing process.

28 Oct 2014

UPDATE 1-India's Ranbaxy books first profit in 6 quarters on exclusive drug launch

* Shares rise 6 pct, outpacing market (Adds details on results, shares, context)

28 Oct 2014

India's Ranbaxy posts Q2 profit

MUMBAI, Oct 28 - Indian generic drugmaker Ranbaxy Laboratories Ltd, which is in the process of being acquired by larger rival Sun Pharmaceutical Industries Ltd , reported a profit in its second quarter.

28 Oct 2014

INDIA PRESS-Ranbaxy may lose heartburn drug Nexium exclusivity - Business Standard

Note: Reuters has not verified this story and does not vouch for its accuracy. (Compiled by Aditya Kondalamahanty in Bangalore)

26 Oct 2014

INDIA PRESS-Ranbaxy staff get pay-cut shield in Sun buyout - Business Standard

Note: Reuters has not verified this story and does not vouch for its accuracy. (Compiled by Derek Francis in Bangalore)

19 Oct 2014

India's Ranbaxy to pay $40 million to settle Texas Medicaid pricing litigation

MUMBAI - Indian generic drugmaker Ranbaxy Laboratories Ltd said it has agreed to pay $39.75 million to settle litigation concerning its participation in Texas Medicaid, the U.S. federal-state healthcare program for people with low incomes.

16 Oct 2014

UPDATE 1-India's Ranbaxy to pay $40 mln to settle Texas Medicaid pricing litigation

* Ranbaxy shares up 0.6 percent in Mumbai (Adds settlement details, analyst views, updates share price)

16 Oct 2014

India's Ranbaxy to pay $40 mln to settle Texas Medicaid pricing litigation

MUMBAI, Oct 16 - Indian generic drugmaker Ranbaxy Laboratories Ltd said it had agreed to pay $39.75 million to settle litigations concerning its participation in Texas Medicaid, the US federal-state healthcare program for the poor.

16 Oct 2014

INDIA PRESS-Ranbaxy's US subsidiary sees 5 top-level exits - Economic Times

Note: Reuters has not verified this story and does not vouch for its accuracy. (Compiled by Derek Francis in Bangalore)

13 Oct 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: Wright Reports
$75.00
Provider: Motilal Oswal Securities Ltd.
$81.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks